Kineta, Inc./de Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Bartoszek Raymond J., was filed 06 Dec 2023.
Kineta, Inc./de: what insiders have been doing
Kineta, Inc./de is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Kineta, Inc./de has had no insider filing for more than a year; the last one goes back to 2 July 2025.
The full history, which starts in 2016, counts 53 purchases against 48 sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and Vetoquinol SA. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended December 2021 · cache
T+90 is the date 90 days after the filing, the exit horizon used to measure each purchase.
- 1,748,473 sharesCommon StockSEC:0000950170-25-093004:1
- 1,001 sharesCommon StockSEC:0000950170-25-093004:2
- 1,000 sharesCommon StockSEC:0000950170-25-093004:3
- 8,553 sharesCommon StockSEC:0000950170-25-093082:1
- 34,654 sharesCommon StockSEC:0000950170-25-093029:1
- 17,794 sharesCommon StockSEC:0000950170-25-092989:0
- 860,377 sharesCommon StockSEC:0000950170-25-093082:0
- 247,933 sharesCommon StockSEC:0000950170-25-093075:0
- 13,794 sharesCommon StockSEC:0000950170-25-093062:0
- 165,156 sharesCommon StockSEC:0000950170-25-093051:0
- 217,333 sharesCommon StockSEC:0000950170-25-093045:0
- 298,464 sharesCommon StockSEC:0000950170-25-093029:0
- 101,891 sharesCommon StockSEC:0000950170-25-093015:0
- 31,000 sharesCommon StockSEC:0000950170-25-093004:0
- 16,571 sharesCommon StockSEC:0000950170-25-092994:0
- 225,000 shares@ US$0.3627.7% of flowCommon StockSEC:0000950170-25-090568:1
- 52,353 shares@ US$0.264.7% of flowCommon StockSEC:0000950170-25-090568:2
- 12,500 shares@ US$0.61116.4% of flowCommon StockSEC:0000950170-25-090568:0
- 6,000 shares0Common StockSEC:0000950170-25-090144:2
- 6,000 shares0Common StockSEC:0000950170-25-090145:2
- 4,706 shares@ US$0.261.0% of flowCommon StockSEC:0000950170-25-090144:1
- 60,300 shares0Common StockSEC:0000950170-25-090134:2
- 6,000 shares0Common StockSEC:0000950170-25-090141:2
- 23,100 shares0Common StockSEC:0000950170-25-090132:2
- 6,000 shares0Common StockSEC:0000950170-25-090129:2
25 of 223 declarations
About Kineta, Inc./de
Kineta, Inc./DE is a U.S.-listed biotechnology company historically quoted on the NASDAQ market in the United States under ticker KANT. The company’s current corporate form followed a reverse merger with Yumanity Therapeutics that closed in December 2022, after which Yumanity changed its name to Kineta, Inc. In SEC filings, Kineta is described as a clinical-stage biotech headquartered in Mercer Island, Washington, United States.([sec.gov](https://www.sec.gov/Archives/edgar/data/0001445283/000119312522311158/d407996dex991.htm?utm_source=openai))
Kineta’s business was built around next-generation immunotherapies aimed at addressing cancer immune resistance. Its lead program was KVA12123, an anti-VISTA monoclonal antibody designed to target a checkpoint pathway involved in the tumor microenvironment and resistance to immunotherapy. The company also disclosed an anti-CD27 agonist antibody in preclinical development. As a development-stage biotech, Kineta depended on R&D execution, clinical progress, intellectual-property protection, regulatory approvals, and ongoing external financing rather than product sales.([sec.gov](https://www.sec.gov/Archives/edgar/data/1445283/000095017024034676/ka-20231231.htm?utm_source=openai))
Read moreShow less
From a competitive standpoint, Kineta was a niche, science-driven player in a crowded oncology landscape dominated by larger, better-capitalized pharmaceutical and biotech groups. Its potential differentiation came from its focus on innate immunity and immune-resistance biology, which management highlighted as a path to differentiated immuno-oncology assets. At the same time, Kineta repeatedly disclosed the typical risks of an early-stage public biotech: limited operating history, no commercial revenue, dependence on capital markets, and the need to advance assets through costly clinical milestones.([sec.gov](https://www.sec.gov/Archives/edgar/data/1445283/000095017024034676/ka-20231231.htm?utm_source=openai))
The most important recent development is that TuHURA Biosciences announced and then completed the acquisition of Kineta on June 30, 2025. The transaction included Kineta’s rights to KVA12123, which was renamed TBS-2025. As a result, KANT should be viewed primarily as a legacy public-company story that transitioned into an acquired asset rather than an ongoing standalone listed biotech. For investors, the key takeaway is that Kineta’s value proposition was tied to a single core immuno-oncology platform and ultimately crystallized through M&A rather than independent commercialization.([sec.gov](https://www.sec.gov/Archives/edgar/data/1445283/000095017025091820/kant-20250630.htm?utm_source=openai))
Written on 17 May 2026 from the filings and market data available that day. Live figures are in the blocks above.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendationsSimilar companies
The weekly insider digest, free
One email on Fridays: the insider clusters and single-name signals worth reading. Unsubscribe in one click.